A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Autologous NK cell therapy can treat a variety of malignancies, but is limited by patient-specific variations in potency and cell number expansion. In contrast, allogeneic NK cell lines can overcome many of these limitations. Cells from the permanent NK-92 line are constitutively activated, lack inh...
में बचाया:
| मुख्य लेखकों: | , , , , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
2017
|
| ऑनलाइन पहुंच: | https://doi.org/10.18632/oncotarget.19204 http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=19204&path%5B%5D=61489 |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|